U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07378579) titled 'An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001' on Dec. 10, 2025.
Brief Summary: This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants,
Study Start Date: June 21, 2024
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteer
Intervention:
DRUG: ESK-001
Single oral dose of ESK-001 in participants
DRUG: Moxifloxacin (400 mg)
positive control
DRUG: Placebo
ESK-001-matched placebo
Recruitment Status: COMPLETED
Sponsor: Alumis Inc
Published by HT Digital Con...